F8 and hemophilia: Furthermore, recent advances in the Hemophilia A research field described that conjugating the coagulation factor VIII (FVIII) to a human IgG1 Fc-portion not only drastically improved the half-life of the drug, but also reduced the generation of anti-drug antibody towards FVIII by inducing a tolerogenic environment, hence providing a better protection against the hemorrhagic disorder (44, 45).